Abstract
Objectives: Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer's disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ).
Methods: We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and Rflurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death.
Results: Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.
Keywords: Alzheimer's disease, non-steroidal anti-inflammatory drugs, calcium, mitochondria, amyloid β oligomers, N-methyl-D-aspartate.
Current Alzheimer Research
Title:Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake
Volume: 15 Issue: 6
Author(s): Sara Sanz-Blasco, Maria Calvo-Rodríguez, Erica Caballero, Monica Garcia-Durillo, Lucia Nunez and Carlos Villalobos*
Affiliation:
- Institute of Molecular Biology and Genetics (IBGM), National Research Council of Spain (CSIC), Valladolid,Spain
Keywords: Alzheimer's disease, non-steroidal anti-inflammatory drugs, calcium, mitochondria, amyloid β oligomers, N-methyl-D-aspartate.
Abstract: Objectives: Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer's disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ).
Methods: We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and Rflurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death.
Results: Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.
Export Options
About this article
Cite this article as:
Sanz-Blasco Sara, Calvo-Rodríguez Maria, Caballero Erica, Garcia-Durillo Monica, Nunez Lucia and Villalobos Carlos*, Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake, Current Alzheimer Research 2018; 15 (6) . https://dx.doi.org/10.2174/1567205015666171227154016
DOI https://dx.doi.org/10.2174/1567205015666171227154016 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets Thioflavin-S Staining of Bacterial Inclusion Bodies for the Fast, Simple, and Inexpensive Screening of Amyloid Aggregation Inhibitors
Current Medicinal Chemistry Non-Pharmacological Treatments for ADHD in Youth
Adolescent Psychiatry Neural Correlates in Patients with Major Affective Disorders: An fMRI Study
CNS & Neurological Disorders - Drug Targets Dangerous Liaisons between Beta-Amyloid and Cholinergic Neurotransmission
Current Pharmaceutical Design DL-3-n-Butylphthalide, an Anti-Oxidant Agent, Prevents Neurological Deficits and Cerebral Injury Following Stroke per Functional Analysis, Magnetic Resonance Imaging and Histological Assessment
Current Neurovascular Research Diabetes Care: Risk Factors, Prediction, Prevention, and Individualized Treatment
Infectious Disorders - Drug Targets Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease
Current Alzheimer Research Positron Emission Tomography in Neuroimaging - An Update
Current Medical Imaging Neurolological Disorders and Neuroprotection After Heart Surgery
Recent Patents on CNS Drug Discovery (Discontinued) TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Editorial [Hot Topic: Alzheimers Disease: Highlights from Research on Hormones, Growth Factors and Signaling Pathways (Debomoy K. Lahiri)]
Current Alzheimer Research Complex Interactions between Phytochemicals. The Multi-Target Therapeutic Concept of Phytotherapy
Current Drug Targets Current Strategies and Novel Drug Approaches for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases
Current Vascular Pharmacology Molecular Basis of Inflammation and Insulin Resistance in Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Telmisartan Promotes Potential Glucose Homeostasis in Stroke-Resistant Spontaneously Hypertensive Rats via Peroxisome Proliferator-Activated Receptor γ Activation
Current Neurovascular Research New Assay for Old Markers-Plasma Beta Amyloid of Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Multivariate Analysis of Magnetic Resonance Imaging Signals of the Human Brain
Current Topics in Medicinal Chemistry